Clinical trials
Prostate Cancer Recurrent clinical trials
Below are recruiting prostate cancer recurrent clinical trials, each written for real people, not researchers. We’re tracking 246 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05176483RecruitingPhase 1
New drug combinations for advanced solid tumors
This trial tests a new drug called zanzalintinib, which may slow or shrink various types of advanced cancer. It is given together with other cancer treatments, and the study is looking at many different cancers including kidney, prostate, bladder, lung, liver, and more.
Phoenix, ArizonaAges 18 years+ - NCT07711002RecruitingPhase 3
Saruparib with standard therapy for metastatic hormone-sensitive prostate cancer
This trial tests a new drug called saruparib, which may help keep prostate cancer from growing. It is for men whose cancer has spread and who have already received certain treatments. The study combines saruparib with a standard hormone therapy to see if it works better than the hormone therapy alone.
Hot Springs, ArkansasAges 18 years+ - NCT07839767Recruiting
Personalized treatment to prevent liver cancer recurrence
This study uses a 3D-printed model of your liver tumor to help doctors choose treatment that may prevent the cancer from coming back after surgery. The model predicts how your tumor might respond, so you get the most effective therapy.
Hong KongAges 18 years+ - NCT07707232Recruiting
Using AI to read PSMA PET/CT reports for prostate cancer
This trial uses a computer program (large language model) to help doctors read Chinese PSMA PET/CT reports. The goal is to see if the AI can accurately identify key details about prostate cancer, like where it has spread, which may help make staging and treatment decisions faster.
Wenzhou, ZhejiangAges 18 years+ - NCT06398613Recruiting
Using PSMA PET scan before prostate cancer surgery
This trial is testing whether a special scan (PSMA PET/CT) before surgery can help doctors decide if you need to remove lymph nodes. It is for men with high-risk prostate cancer who are already planning to have robot-assisted prostate removal.
OsloAges 18 years+ - NCT07514065RecruitingPhase 1
TSL2109 Safety and Effectiveness Study in Advanced Cancers
This early-stage study tests a new drug called TSL2109 in patients with advanced solid cancers that haven't responded to standard treatment. Researchers want to find the right dose, understand how the body processes it, and see if it can slow or shrink tumors, with special focus on certain prostate and breast cancers.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07259213RecruitingPhase 1/Phase 2
Study of a new drug (161Tb-RAD402) for men with advanced prostate cancer
This trial tests a new radioactive drug designed to target and destroy prostate cancer cells. It is for men whose cancer has continued to grow despite hormone therapy and other treatments like enzalutamide or abiraterone.
Wollongong, New South WalesAges 18 years+ - NCT07172685Recruiting
Triple therapy plus HIFU for high-tumor-burden prostate cancer
This trial tests a combination of hormone therapy, chemotherapy (docetaxel), and a targeted drug (apalutamide) with a focused ultrasound procedure (HIFU) for men with prostate cancer that has spread to many bones or organs. It may help control the cancer more effectively.
Jinan, ShandongAges 18 years+ - NCT06981026Recruiting
Checking if remote health coaching helps before prostate surgery
This study tests whether using a smartphone or computer to get health coaching before prostate cancer surgery helps people recover faster and have better results. You will be asked to exercise and track your health at home while staying connected with your care team.
OlomoucAges 40–80 - NCT05033301Recruiting
Nurse Ned Clinic support for prostate cancer survivors
This study tests a nurse-led clinic (“Nurse Ned Clinic”) to see how well it supports men after curative (potentially curative) prostate cancer treatment. It may help you manage follow-up care during survivorship if you are at low risk of cancer coming back.
Toronto, OntarioAges 18 years+ - NCT06780670RecruitingPhase 2/Phase 3
Comparing a new treatment to standard care for advanced prostate cancer
This study tests a new drug (AAA817) against the usual treatments for men with advanced prostate cancer that has stopped responding to a type of targeted radiation therapy (Lu-PSMA). The goal is to see if the new drug can slow the cancer's growth better than standard options.
Scottsdale, ArizonaAges 18–100 - NCT06084338RecruitingPhase 2
Focused Radiation Therapy Without Hormone Therapy for Advanced Prostate Cancer
This trial tests whether giving focused radiation to many cancer spots (SBRT) can work without using testosterone-blocking hormone therapy. It is for men whose prostate cancer has spread and is no longer responding to low testosterone, and who have already tried one of the newer hormone drugs.
West Los Angeles, CaliforniaAges 18 years+ - NCT05939414RecruitingPhase 3
Study of radioactive drug for prostate cancer that has spread a little
This study tests a radioactive drug (177Lu-PSMA-617) compared to no immediate treatment in men with prostate cancer that has returned and spread to a few spots (oligometastatic). It aims to see if this treatment delays the spread of cancer and improves outcomes.
Fayetteville, ArkansasAges 18–100 - NCT03701581RecruitingPhase 2/Phase 3
4-aminopyridine to help erections after prostate nerve surgery
This trial tests whether a medicine called 4-aminopyridine (4AP) can help recover or protect erectile function after “nerve-sparing” prostate surgery. It’s for men with early-stage, non-spread prostate cancer who are scheduled for robotic prostate surgery and have good baseline erections.
Tucson, ArizonaAges 45–75 - NCT00913939Recruiting
MRI-guided high-dose-rate treatment for recurrent prostate cancer
This study tests a targeted radiation approach called high-dose-rate (HDR) brachytherapy, guided by MRI, for certain people with recurrent or higher-risk prostate cancer. It may help deliver radiation more precisely, depending on your cancer type and prior treatments.
Toronto, OntarioAges 18 years+ - NCT06869473RecruitingPhase 2
Cetuximab, chemo, and avelumab for head and neck cancer
This trial tests a combination of targeted therapy (cetuximab) and immunotherapy (avelumab) plus chemotherapy as a first treatment for people with head and neck cancer that has come back or spread. The goal is to see if adding these medicines helps control the cancer longer.
Cagliari, CAGLIARIAges 18 years+ - NCT05260671RecruitingPhase 2
Penpulimab plus cetuximab for advanced head and neck cancer
This trial studies penpulimab (an immune medicine) combined with cetuximab (an antibody drug) for recurrent or metastatic squamous cell head and neck cancer that cannot be treated with surgery or radiation. It aims to shrink tumors and improve survival in people whose tumor shows a specific immune marker (PD-L1).
Changchun, JilinAges 18–80 - NCT06359275RecruitingPhase 2
Combination therapy for locally advanced or recurrent pancreatic cancer
This trial tests a combination of immunotherapy (PD-1), chemotherapy, and a special type of radiation called PULSAR for patients with locally advanced pancreatic cancer or cancer that has come back only in the pancreas area. The goal is to see if this approach can shrink tumors or keep them from growing.
ShanhaiAges 18–75 - NCT05884320RecruitingPhase 2
Sacituzumab govitecan for advanced salivary gland cancers
This Phase 2 trial tests sacituzumab govitecan, an anti-cancer medicine, in people with recurrent or metastatic (coming back or spread) secretory gland cancers or related salivary gland cancers. It aims to see how well the treatment can shrink tumors and control disease when surgery or radiation is not a cure.
Houston, TexasAges 18 years+ - NCT05799144RecruitingPhase 2
Pembrolizumab plus investigational HPV drugs for throat cancer
This Phase 2 trial studies pembrolizumab (an immune therapy) combined with investigational treatment(s) pBI-11 and TA-HPV for advanced or recurrent oropharyngeal cancer that is HPV-positive and has certain immune marker levels (PD-L1 CPS ≥ 1). It may help your immune system better attack cancer.
Birmingham, AlabamaAges 18 years+ - NCT06447103RecruitingPhase 2
New scan to find kidney cancer after surgery
This trial tests a special PET scan to see if it can better find leftover kidney cancer after surgery compared to a standard CT scan. You may qualify if you had kidney cancer surgery within the last 4-16 weeks and are at high risk of the cancer coming back.
Los Angeles, CaliforniaAges 18 years+ - NCT07725796RecruitingPhase 1
Study of UGN-501 for recurrent bladder cancer
This study tests an experimental medicine called UGN-501 given directly into the bladder. It is for people whose bladder cancer has come back despite previous treatments, such as BCG therapy. The goal is to find the best dose and see how safe and effective it is.
Queen Creek, ArizonaAges 18 years+ - NCT05337397Recruiting
Outpatient laser treatment for repeat low-grade bladder tumors
This trial tests an outpatient laser procedure to remove recurring low-grade, non-solid bladder tumors. It may help prevent or control tumor growth with treatment done outside the hospital, if you meet the tumor and health criteria.
AarhusAges 18 years+ - NCT03418961RecruitingPhase 3
Study of heart-risk management for metastatic HER2 breast cancer
This trial follows people with metastatic HER2-positive breast cancer who are at higher risk for heart damage while on HER2-targeted therapy. Some participants are randomly assigned to different monitoring/heart-protection approaches to see what best helps keep the heart safe.
Anchorage, AlaskaAges 18 years+
Hear when a new Prostate Cancer Recurrent trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for prostate cancer recurrent?
- Yes. Clin2 currently lists 246 recruiting prostate cancer recurrent studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a prostate cancer recurrent trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a prostate cancer recurrent trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.